成果報告書詳細
管理番号20140000000505
タイトル*平成25年度中間年報 「がん超早期診断・治療機器の総合研究開発 超早期高精度診断システムの研究開発 画像診断システムの研究開発 がんの性状をとらえる分子プローブ等の研究開発 (がんの特性識別型分子プローブ) 」
公開日2015/3/25
報告書年度2013 - 2013
委託先名日本メジフィジックス株式会社
プロジェクト番号P10003
部署名バイオテクノロジー・医療技術部
和文要約
英文要約Title: The Advanced Research and Development Project on Diagnosis and Treatment for Early Stage of Cancer. Research and Development Project on High-speck Diagnostic Equipment for Medical Imaging. Research and Development Project on Medical Imaging System. Research and Development Project on Molecular Imaging Probes for Cancer Characterization. Molecular Imaging Probes for Cancer Characterization. (FY2010-2014) Annual Report: FY2013

The goal of this R&D project is to develop the multi-modalities imaging methods, combining Positron Emission Tomography (PET) and other imaging devices such as MRI, for the purpose of optimizing the molecular-targeted cancer therapeutics in the personalized clinical settings. In collaboration with Kyoto University, we have decided to develop new PET imaging probes for (1) pancreatic and (2) prostate cancers. Molecular designs of these PET imaging probes would be based on pathophysiological properties and treatment strategies of each tumor. Nihon Medi-Physics (NMP) is in charge of preclinical safety evaluations of the new PET imaging probes to be developed by Kyoto University. This annual report briefly summarizes the R&D activities made by NMP for this project in fiscal year 2013.
In FY2013, NMP initiated safety studies of new prostate cancer imaging probes targeting PSMA developed by Kyoto Univ. Expanded single dose toxicity studies using normal mice were performed by CRO in compliance with GLP. The dose of the test substances was selected among 0, 4.0 and 13.2 μg/kg. After two weeks observation, the test animals were sacrificed and major organs were inspected visually. Data analysis is in progress. In addition, NMP is investigating the possibility to expand the usefulness of this PSMA imaging agent to the other diseases.
Preliminary market research for the new PET imaging probes in the area of pancreatic and prostate cancers were also conducted. From the results of the survey to key opinion leaders in this field, it is concluded that pancreatic β-cell imaging is a very promising tool to replace the current invasive method to detect the lesion of insulinoma.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る